Anti-ZEBOV Glycoprotein Reference Antibody (Maftivimab, RUO) (VK623056)

Name: Anti-ZEBOV Glycoprotein Reference Antibody (Maftivimab, RUO)
Brand: abinScience
SKU: VK623056
Price: 176 USD
Availability: InStock

データシート製品共有情報コピー

価格(USD):

スペック:

100ug
1mg
5mg
10mg
25mg
50mg
100mg

数量:

お問い合わせ

概要
イメージ
参考文献
データシート
SDS

概要

カタログ番号	VK623056
種反応性	Zaire ebolavirus (ZEBOV) (Zaire Ebola virus)
アプリケーション	ELISA, Bioactivity: FCM, Functional assay, Research in vivo
宿主種	Human
クローン性	Monoclonal
アイソタイプ	IgG1, kappa
生物学的活性	Maftivimab binds with high affinity to the recombinant histidine-tagged extracellular domain protein of Ebola virus Makona strain glycoprotein (K d = 2.97 × 10 nM [1]). Maftivimab potently neutralizes Ebola pseudovirus particles in vitro, with an IC 50 of 0.17 nM [1].
ターゲット	Envelope glycoprotein, GP, GP1, GP1,2, GP1,2-delta, GP2, Shed GP
エンドトキシンレベル	< 10 EU/mg
純度	>95% as determined by SDS-PAGE.
精製	Protein A/G purified from cell culture supernatant.
アクセッション番号	Q05320
形態	Liquid
保存バッファー	0.01M PBS pH 7.4. データシートのハードコピーまたはロット固有のCOAに記載された具体的なバッファー情報を参照してください。
安定性と保存	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
別名	REGN-3470-3471-3479, REGN-3470/REGN-3471/REGN-3479, INMAZEB™(odesivimab-ebgn, maftivimab, andatoltivimab), 2135632-36-7
背景	Envelope glycoprotein (GP) is a ~74 kDa protein. Trimeric GP1,2 complexes form the virion surface spikes and mediate the viral entry processes, with GP1 acting as the receptor-binding subunit and GP2 as the membrane fusion subunit. At later times of infection, down-regulates the expression of various host cell surface molecules that are essential for immune surveillance and cell adhesion. Down-modulates several integrins including ITGA1, ITGA2, ITGA3, ITGA4, ITGA5, ITGA6, ITGAV and ITGB1. This decrease in cell adhesion molecules may lead to cell detachment, contributing to the disruption of blood vessel integrity and hemorrhages developed during infection (cytotoxicity) (Probable). Interacts with host TLR4 and thereby stimulates the differentiation and activation of monocytes leading to bystander death of T-lymphocytes. 1. Simmons, G. et al. (2002) Journal of virology 76, 2518-28. PMID: 11836430 2. Takada, A. et al. (2000) Virology 278, 20-6. PMID: 11112476 3. Iampietro, M. et al. (2017) PLoS pathogens 13, e1006397. PMID: 28542576 4. Edri, A. et al. (2018) Frontiers in immunology 9, 1428. PMID: 30013549 5. Vande Burgt, NH. et al. (2015) Viruses 7, 5587-602. PMID: 26516900 6. Brinkmann, C. et al. (2016) Journal of virology 90, 11075-11086. PMID: 27707924 7. González-Hernández, M. et al. (2018) Journal of virology 92. PMID: 29669839 8. Rizk, MG. et al. (2017) Journal of virology 91. PMID: 28878074
参考文献	1. Markham A. REGN-EB3: First Approval. Drugs. 2021 Jan;81(1):175-178. [VK623056] 2. Gaudinski MR, et al. Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study. Lancet. 2019 Mar 2;393(10174):889-898. [VK623056]
注意事項	For research use only. Not suitable for clinical or therapeutic use.